{
  "docId": "019de074-a4f4-74e1-8870-171c8951fea8",
  "docSlug": "e0247ed9fbf6e59fd6aeeea6f3eacc2d",
  "documentTitle": "23andMe | Investor Presentation Deck | 57 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 48,
  "pageCount": 57,
  "prevPage": 47,
  "nextPage": 49,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a4f4-74e1-8870-171c8951fea8/48",
  "deckHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8",
  "deckJsonHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8.json",
  "deckAnchorHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8#slide-48",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "list",
      "text": "Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models; GSK'608 is a high affinity monoclonal antibody against CD96; GSK'608 is currently being evaluated in an ongoing Phase 2 study; In January 2022, 23andMe elected to take a royalty option on GSK'608. As a result, GSK is now solely responsible for the development of GSK'608.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc034976-7291-4434-8faa-3de4e48123a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "title",
      "text": "The GSK'608 Program is a Prime Example of the Value 23andMe Brings to Drug Discovery and Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f52b5c4-4ea3-485e-9d36-617f971a2c68",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 48,
      "from": 36,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "25bf5fec-1759-4ae6-8d05-5ad619b628ea",
      "evidence": "The deck presents 23andMe's research and development pipeline and its immuno-oncology programs",
      "position": 2,
      "objective": "What are the opportunities for 23andMe in therapeutics development?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}